Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sarita Kapila
MS
Sarita Kapila
Morgan Stanley
Wall Street Analyst
★★★☆☆
#1336
on 13Foresight · ranked by our own returns
33%
Success Rate
-10.9%
Average Return
1 of 3 calls profitable · -32.8% vs benchmark
📈 Across the calls we could measure, roughly 33% of Sarita Kapila's ratings turned a profit when each position was held for 2 year — averaging -10.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

14 Buy 4 Hold 13 Sell
Sarita's Stock Coverage 11 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return
SNY
Sanofi
 May 01, 2026 HOLD Strong Buy
+74.8% avg upside
20 analysts
$52.00
22.27% Upside
 +1.4%
CH:ROP
Roche Holding AG
 Apr 24, 2026 HOLD Buy
+2.1% avg upside
23 analysts
$295.00
10.03% Downside
 ·
GB:AZN
AstraZeneca
 Apr 13, 2026 BUY Strong Buy
+10.9% avg upside
26 analysts
$16500.00
22.49% Upside
 ·
RHHBY
Roche Holding
 Apr 07, 2026 SELL Buy
-1.9% avg upside
14 analysts
$46.00
9.96% Downside
 -4.3%
GB:0NZT
UCB SA
 Mar 06, 2026 HOLD Buy
-13.5% avg upside
19 analysts
$260.00
4.23% Upside
 ·
GB:GSK
GlaxoSmithKline
 Mar 02, 2026 SELL Hold
-4.4% avg upside
25 analysts
$1700.00
13.85% Downside
 ·
FR:SAN
Sanofi
 Sep 08, 2025 BUY Strong Buy
+33.4% avg upside
30 analysts
$100.00
33.47% Upside
 ·
SE:SOBI
Swedish Orphan Biovitrum AB
 May 04, 2023 HOLD Strong Buy
-15.3% avg upside
6 analysts
$257.88
41.46% Downside
 ·
ES:GRF
Grifols
 Feb 08, 2023 BUY Buy
+63.8% avg upside
12 analysts
$16.00
77.79% Upside
 ·
GRFS
Grifols SA
 Feb 08, 2023 BUY Buy
+241.0% avg upside
12 analysts
$18.43
147.20% Upside
 -29.7%
ZLDPF
Zealand Pharma
 Nov 16, 2022 HOLD Buy
+92.5% avg upside
11 analysts
$36.51
18.91% Downside
 ·
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sarita Kapila — Frequently Asked Questions
How accurate are Sarita Kapila's stock ratings?
Based on the calls 13Foresight could measure, about 33% of Sarita's ratings were profitable over a one-year hold, with an average return of -7.5% per rating, or -20.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Sarita ranked on 13Foresight?
Sarita Kapila is currently ranked #1336 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sarita cover?
Sarita most recently has ratings on SNY, CH:ROP, GB:AZN, RHHBY, GB:0NZT, GB:GSK, FR:SAN, SE:SOBI, ES:GRF, GRFS, ZLDPF. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.